AR108753A1 - Uso de insulina para promover el vaciamiento gástrico, composición y kit - Google Patents

Uso de insulina para promover el vaciamiento gástrico, composición y kit

Info

Publication number
AR108753A1
AR108753A1 ARP170100743A ARP170100743A AR108753A1 AR 108753 A1 AR108753 A1 AR 108753A1 AR P170100743 A ARP170100743 A AR P170100743A AR P170100743 A ARP170100743 A AR P170100743A AR 108753 A1 AR108753 A1 AR 108753A1
Authority
AR
Argentina
Prior art keywords
insulin
gastric emptying
composition
kit
promote gastric
Prior art date
Application number
ARP170100743A
Other languages
English (en)
Inventor
Tal Atarot
Michal Olshansky
Original Assignee
Nutrinia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrinia Ltd filed Critical Nutrinia Ltd
Publication of AR108753A1 publication Critical patent/AR108753A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un método para promover el vaciamiento gástrico en un sujeto que lo necesite, que comprende la etapa de administrar por vía enteral una cantidad efectiva de insulina o una composición que la comprende al sujeto, promoviendo con ello el vaciamiento gástrico en dicho sujeto. Reivindicación 14: El procedimiento de la reivindicación 1, en el que la insulina se encapsula en una matriz de encapsulación. Reivindicación 15: El método de la reivindicación 14, en el que la matriz de encapsulación comprende maltodextrina.
ARP170100743A 2016-03-24 2017-03-27 Uso de insulina para promover el vaciamiento gástrico, composición y kit AR108753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312473P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
AR108753A1 true AR108753A1 (es) 2018-09-26

Family

ID=59900798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100743A AR108753A1 (es) 2016-03-24 2017-03-27 Uso de insulina para promover el vaciamiento gástrico, composición y kit

Country Status (19)

Country Link
US (1) US10046032B2 (es)
EP (1) EP3432861B1 (es)
JP (1) JP7102347B2 (es)
KR (1) KR20180123114A (es)
CN (1) CN109152733A (es)
AR (1) AR108753A1 (es)
AU (1) AU2017237164A1 (es)
BR (1) BR112018069444A2 (es)
CA (1) CA3018215C (es)
ES (1) ES2957891T3 (es)
HR (1) HRP20230972T1 (es)
HU (1) HUE062950T2 (es)
IL (1) IL261898A (es)
MX (1) MX2018011512A (es)
PL (1) PL3432861T3 (es)
RS (1) RS64623B1 (es)
RU (1) RU2018133604A (es)
SG (1) SG11201808154XA (es)
WO (1) WO2017165789A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017237164A1 (en) 2016-03-24 2018-10-11 Nutrinia Ltd. Use of insulin for promoting gastric emptying

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
DE3789965T2 (de) 1986-08-28 1994-10-13 Enzacor Pty Ltd Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren.
FR2606597B1 (fr) 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4944944A (en) 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5013569A (en) 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US5418010A (en) 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
DE4100920A1 (de) 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5360614A (en) 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
ATE207312T1 (de) 1995-06-29 2001-11-15 Nestle Sa Verfahren zur verkapselung eines kernmaterials mit einem polymer durch hochdruckbehandlung
JPH10155428A (ja) 1996-12-04 1998-06-16 Shida Kanzume Kk 毛づや改善剤及び毛づやの改善方法、並びに健康食品
ID23411A (id) 1997-03-27 2000-04-20 Bristol Myers Squibb Co Penggunaan asam dokosaheksanoat dan asam arakidonat yang meningkatkan pertumbuhan bayi belum cukup bulan
JPH119196A (ja) 1997-06-24 1999-01-19 Meiji Seika Kaisha Ltd キトサンによる家畜の損耗防止の方法
TR199901008T1 (xx) 1997-09-09 2000-02-21 Select Release, L.C. Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6399090B1 (en) 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
ATE413889T1 (de) 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000116320A (ja) 1998-10-13 2000-04-25 Bingu Gure:Kk 乳酸菌カプセル入りヨーグルト及びその製造方法
GB2345836A (en) 1999-01-25 2000-07-26 Charleville Res Animal milk replacer
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6548043B1 (en) 1999-08-03 2003-04-15 Metabolic Solutions, Inc. Measurement of gastric emptying
US6774128B2 (en) 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CN100396769C (zh) 2000-05-25 2008-06-25 雀巢制品公司 宠物食物使用的新益生菌
EP1214892B1 (en) 2000-12-15 2005-03-09 Quest International B.V. A moisture and oxygen stable composition and a process for obtaining said composition
JP2002209513A (ja) 2000-12-15 2002-07-30 Bingu-Gure:Kk 栄養成分を含有する多数のカプセル入り強化牛乳
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
CN1531399A (zh) 2001-05-14 2004-09-22 瓦西里・彼得罗维奇・安德烈丘克 预防碘缺乏和优化碘代谢的生物活性食品添加剂和生物活性饲料添加剂,以及含该添加剂的食品和饲料
US20050226905A1 (en) 2001-05-22 2005-10-13 Tien Canh L Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20030175403A1 (en) 2002-03-14 2003-09-18 Gurin Michael H. Potentiated bioactive additives and method of use
US20030175382A1 (en) 2002-03-14 2003-09-18 Dally Vernetta L. Heat released encapsulated yeast
CN1656205A (zh) 2002-07-01 2005-08-17 诺和酶股份有限公司 颗粒的稳定
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US8877232B2 (en) 2003-06-20 2014-11-04 Nutrinia Ltd. Bioactive compounds protection method and compositions containing the same
WO2005115473A2 (en) 2004-05-24 2005-12-08 Nutrinia Ltd. Nutritional food and feed, composition, processing and method of use
US8026211B2 (en) 2004-06-02 2011-09-27 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
GB0502795D0 (en) 2005-02-10 2005-03-16 Univ Cambridge Tech Treatment of very low birthweight (vlbw) infants
CA2621577C (en) 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
AU2008259372B2 (en) 2007-06-07 2014-07-10 Elgan Pharma Ltd Means and methods for enhancing weight gain in poultry
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
ES2603328T3 (es) 2010-10-21 2017-02-27 Swedish Orphan Biovitrum Ab (Publ) Método para incrementar la tasa de crecimiento de lactantes humanos
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CA2870091A1 (en) 2012-04-18 2013-10-24 Nutrinia Ltd. Growth enhancement of infants
US20150209412A1 (en) 2012-05-31 2015-07-30 Nutrinia Ltd. Insulin-containing infant formula
AU2017237164A1 (en) 2016-03-24 2018-10-11 Nutrinia Ltd. Use of insulin for promoting gastric emptying

Also Published As

Publication number Publication date
AU2017237164A1 (en) 2018-10-11
RS64623B1 (sr) 2023-10-31
JP2019509317A (ja) 2019-04-04
US10046032B2 (en) 2018-08-14
EP3432861C0 (en) 2023-07-12
ES2957891T3 (es) 2024-01-29
PL3432861T3 (pl) 2023-12-18
US20170319663A1 (en) 2017-11-09
EP3432861A4 (en) 2019-10-23
CA3018215A1 (en) 2017-09-28
BR112018069444A2 (pt) 2019-10-08
JP7102347B2 (ja) 2022-07-19
MX2018011512A (es) 2019-02-07
CA3018215C (en) 2023-10-03
HRP20230972T1 (hr) 2023-12-08
EP3432861A1 (en) 2019-01-30
RU2018133604A (ru) 2020-04-24
IL261898A (en) 2018-10-31
WO2017165789A1 (en) 2017-09-28
EP3432861B1 (en) 2023-07-12
SG11201808154XA (en) 2018-10-30
HUE062950T2 (hu) 2023-12-28
CN109152733A (zh) 2019-01-04
KR20180123114A (ko) 2018-11-14

Similar Documents

Publication Publication Date Title
DOP2015000190A (es) Cápsula de porción y sistema
CL2018001646A1 (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. (divisional solicitud 201602105)
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
DOP2015000143A (es) Cápsula de porción y procedimiento para la preparación de una bebida con una cápsula de porción
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR053803A1 (es) Uso de acido pinolenico
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2015002914A1 (es) Tratamiento de la diabetes mellitus mediante formulaciones de la insulinas de acción prolongada
CR20120140A (es) Composiciones de liberación controlada
PE20181095A1 (es) Envase blister
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
PE20150190A1 (es) Formulacion farmaceutica
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
PE20211864A1 (es) Uso de lecitinas como biocida contra artropodos
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.